Investor Video Series: Spotlight on the Occuity PM1 Pachymeter
- Richard Kadri-Langford
- Nov 19
- 2 min read
As part of our investor video series exploring the technology and commercial opportunities behind Occuity’s product portfolio, our latest release takes a closer look at the PM1 Pachymeter — the first device built on our patented non-contact optical platform and the foundation on which our broader strategy is being built.
The PM1 represents a major milestone for Occuity: our first regulatory-cleared, revenue-generating product, now in the hands of distributors worldwide. This video explains how the PM1 was conceived, engineered and brought to market — and why its success provides strong validation for everything that comes next.
What the PM1 Represents for Occuity and Our Investors
The PM1 is far more than a standalone product. It is proof that our optical platform works, that it can be commercialised, and that it can be scaled into multiple devices serving multiple clinical markets.
The video charts the PM1’s full journey:
From the needs and uses of pachymetry
Through CE marking, MDR compliance and regulatory approval
And finally to commercial launch via a growing international distributor network
For investors, the PM1 demonstrates:
Successful commercialisation of Occuity’s patented optical platform
A scalable architecture, enabling future devices (AX1 Axiometer™, Oculomics screening devices, Indigo glucose meter) to be built more efficiently
A clear route to market, with strong demand in glaucoma assessment, refractive surgery and community eye care
The credibility of our engineering and regulatory teams, evidenced by bringing a Class IIa device from concept to market
The PM1 is the first step in a device family designed to address multi-billion-dollar markets in ophthalmology, myopia management and systemic disease screening.
Why This Matters in the Context of Our Mission
Our goal is to improve the lives of millions of people through earlier detection, better monitoring and non-invasive screening of major health conditions such as glaucoma, myopia, diabetes and Alzheimer’s.
The PM1 is the first commercial expression of that vision.
It proves that non-contact, handheld devices can:
Deliver accurate, clinically meaningful measurements
Improve patient comfort by eliminating contact and anaesthetic drops
Enable faster, more accessible assessment in high-street practices
Reduce bottlenecks in busy clinics
Integrate into broader screening programmes
As we expand into myopia management with the AX1 and into systemic disease screening through our Oculomics products, the PM1 stands as the technical and commercial foundation beneath it all.
Follow Occuity’s Investment Round on Republic
Occuity is currently raising on Republic.Learn more, view our pitch deck and join the discussion:
If you have any questions, I’d be happy to answer them here or in the Republic discussion forum.
Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong.Take 2 minutes to learn more: https://europe.republic.com/pages/risk-warnings